Research site

Memphis, Tennessee 38401

10 studies enrolling now · 160 studies all time

What they study most

Active Systemic Lupus Erythematosus, Acute Coronary Syndrome, Acute Coronary Syndromes, Acute Lymphoblastic Leukemia, Advanced Solid Tumors, Advanced Squamous Non-Small Cell Lung Cancer, Affective Psychosis, Bipolar, Aggressive B-cell Lymphomas, Alcohol Dependence, Anemia, Anemia in Chronic Kidney Disease Patients Not on Dialysis, Anxiety

Studies at this site

• A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin — Recruiting now
• Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma — Recruiting now
• A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus — Recruiting now
• Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer — Recruiting now
• A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus — Recruiting now
• A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event — Recruiting now
• Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 — Recruiting now
• Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations — Recruiting now
• Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function — Recruiting now
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) — Recruiting now
• Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS — Recruiting now
• A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension — Completed
• A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. — Running, not enrolling
• Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus — Running, not enrolling
• A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma — Running, not enrolling
• Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) — Running, not enrolling
• Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer — Running, not enrolling
• Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab — Enrolling by invitation
• Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC — Running, not enrolling
• A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS — Running, not enrolling
• A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure. — Running, not enrolling
• A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) — Running, not enrolling
• A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features — Running, not enrolling
• A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02) — Running, not enrolling
• Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations — Running, not enrolling
• Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment — Running, not enrolling
• A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer. — Completed
• Study of ALXN2220 Versus Placebo in Adults With ATTR-CM — Running, not enrolling
• MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women — Completed
• Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms — Completed
• Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis — Stopped early
• A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease — Completed
• A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome — Completed
• A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease — Stopped early
• A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA) — Completed
• Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease — Completed
• An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer — Stopped early
• Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC — Completed
• QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer — Stopped early
• QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer — Completed
• Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial) — Completed
• A Phase 2b Diabetic Kidney Disease Study — Completed
• Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old — Completed
• Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk — Completed
• Expanded Access Protocol - Blinatumomab in Pediatric & Adolescent Subjects With Relapsed/Refractory B-precursor ALL — NO_LONGER_AVAILABLE
• A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY) — Completed
• Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised Children — Completed
• Study of Tremelimumab in Patients With Advanced Solid Tumors — Completed
• Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease — Stopped early
• Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis — Completed